Adam III - Nexgel Chief Officer

NXGL Stock  USD 3.27  0.03  0.91%   

Insider

Adam III is Chief Officer of Nexgel Inc
Age 47
Address 2150 Cabot Boulevard West, Langhorne, PA, United States, 19047
Phone215 702 8550
Webhttps://nexgel.com

Nexgel Management Efficiency

The company has return on total asset (ROA) of (0.2316) % which means that it has lost $0.2316 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6431) %, meaning that it created substantial loss on money invested by shareholders. Nexgel's management efficiency ratios could be used to measure how well Nexgel manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.39. The value of Return On Capital Employed is expected to slide to -0.49. At this time, Nexgel's Intangible Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.13 this year, although the value of Total Current Assets will most likely fall to about 3.9 M.
Nexgel Inc currently holds 2.8 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Nexgel Inc has a current ratio of 4.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Nexgel's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Bruno OnkelinxNyxoah
N/A
Esq CPAGlucoTrack
59
Steven MDSharps Technology
62
Robert MBAPredictive Oncology
69
MScEE MBAGlucoTrack
70
Jeremy FefferNyxoah
N/A
David BAGlucoTrack
59
Robert MBANyxoah
77
Barry BerlerSharps Technology
70
Olivier TaelmanNyxoah
53
Alan BlackmanSharps Technology
75
Robert MyersPredictive Oncology
67
Joy GoudieDaxor
N/A
Dorit NahariNyxoah
N/A
BS BScPredictive Oncology
73
DSc ODPredictive Oncology
N/A
Keisha HarcumMilestone Scientific
N/A
Julia KirshnerPredictive Oncology
N/A
Erez BenZviGlucoTrack
46
Theresa FergusonPredictive Oncology
N/A
Henry CremisiDaxor
N/A
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania. Nexgel operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. Nexgel Inc (NXGL) is traded on NASDAQ Exchange in USA. It is located in 2150 Cabot Boulevard West, Langhorne, PA, United States, 19047 and employs 19 people. Nexgel is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Nexgel Inc Leadership Team

Elected by the shareholders, the Nexgel's board of directors comprises two types of representatives: Nexgel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nexgel. The board's role is to monitor Nexgel's management team and ensure that shareholders' interests are well served. Nexgel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nexgel's outside directors are responsible for providing unbiased perspectives on the board's policies.
Adam Levy, President CEO
David Stefansky, Ex Director
Adam III, Chief Officer
Gregory Robb, Vice Operations

Nexgel Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nexgel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Nexgel Inc is a strong investment it is important to analyze Nexgel's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nexgel's future performance. For an informed investment choice regarding Nexgel Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nexgel Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nexgel. If investors know Nexgel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nexgel listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.59)
Revenue Per Share
0.846
Quarterly Revenue Growth
0.234
Return On Assets
(0.23)
Return On Equity
(0.64)
The market value of Nexgel Inc is measured differently than its book value, which is the value of Nexgel that is recorded on the company's balance sheet. Investors also form their own opinion of Nexgel's value that differs from its market value or its book value, called intrinsic value, which is Nexgel's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nexgel's market value can be influenced by many factors that don't directly affect Nexgel's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nexgel's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nexgel is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nexgel's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.